Soft Tissue Sarcoma

PharmaMar Submits European Marketing Authorization Application For ET-743

Published in Gene Therapy Weekly, December 27th, 2001

PharmaMar has submitted an application for its novel antitumor agent, Ecteinascidin-743 (ET-743), for the treatment of advanced soft tissue sarcoma after failure of conventional chemotherapy, to the European Agency for the Evaluation of Medicinal Products (EMEA) and the Swiss Health Authorities.

Approval by the EMEA will allow unified labeling for ET-743 for this indication throughout all member states of the European Union.

ET-743 is the first of a new class of antitumor agents that block the activation of genes in a unique way. ET-743 has multiple effects, such as selective inhibition of expression of key genes (including oncogenes) involved in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-12-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry